Key facts
- Graviton BioScience’s last known valuation is $264.0M (Feb 2024).
- It has raised $93.3M across 4 recorded rounds; the latest was Early Stage VC ($25.0M) in Jan 2024.
- Notable investors include Cormorant Asset Management, Innova Capital Partners, Deep Future, Enavate Sciences, Ovid Therapeutics — 6 tracked in total.
- Graviton BioScience has filed 4 Form Ds with the SEC since 2021, most recently Feb 2024 ($25.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Graviton BioScience
Funding rounds
4 roundsAbout Graviton BioScience
Developer of clinical-stage drugs designed for the treatment of autoimmune, cancer, and other serious diseases. The company platform is dedicated to engineering and developing therapeutics for treating CNS, autoimmune, fibrotic, and other serious diseases, where its other therapeutic compounds play a pivotal role in pathology and offer drug candidates targeting rho-associated protein kinase, a key mediator of cellular contractility and fibrosis, enabling patients to potentially access groundbreaking treatments for a range of debilitating diseases.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Employees
- 43
- Website
- gravitoncorp.com/
- Ownership
- Privately Held (backing)
Graviton BioScience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Graviton BioScience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Graviton BioScience in its N-PORT filings yet. We sweep new filings monthly.